PMID- 20825071
OWN - NLM
STAT- MEDLINE
DCOM- 20101022
LR  - 20151119
IS  - 0023-2157 (Print)
IS  - 0023-2157 (Linking)
VI  - 112
IP  - 4-6
DP  - 2010
TI  - Safety of ranibizumab therapy in wet AMD and the role of vascular endothelial 
      growth factors in physiological angiogenesis.
PG  - 147-50
AB  - Vascular endothelial growth factor - A (VEGF-A), is a major factor implicated in 
      choroidal neovascularisation (CNV) and therefore a target for therapeutic agents 
      in wet age related macular degeneration (AMD). Ranibiuzumab (Lucentis) blocks all 
      active isoforms of VEGF-A and the products of their degradation. It penetrates 
      through all layers of the retina in order to reach the target tissue. It is 
      quickly removed from the system and it is characterised by low level of 
      immunogenicity. The essence of angiogenesis is formation of new vessels by 
      branching and expansion of already existing ones. Angiogenesis is an important 
      physiological process that takes place during the healing of wounds, 
      reconstruction of hypoxic injury and reproduction. However some diseases such as 
      cancer, arthritis, diabetes and neovascular AMD are associated with persistent 
      unregulated angiogenesis. There is an important question whether binding 
      vascular-endothelial growth factors in wet AMD therapies using ranibizumab is 
      correlated with the increase of the incidence of systematic adverse effects 
      (AEs), such as cardiovascular episodes or thrombosis. The aim of this article is 
      to present ranibizumab as a safe drug in treating wet AMD patients. Even though 
      the concentration of Lucentis administered in a dose of 0.3 or 0.5 mg into the 
      vitreous body in the organism is very low, the incidence of AEs during the 
      anti-VEGF therapy was traced. In MARINA and ANCHOR studies, occurrence of 
      possible AEs was observed. No statistically significant differences were shown in 
      the AEs frequency between the patients treated with ranibizumab and the control 
      group, and in correlation with the general population of patients suffering from 
      wet AMD.
FAU - Figurska, Malgorzata
AU  - Figurska M
AD  - Department of Ophthalmology, Military Medical Institute, Warsaw. 
      malgorzata-figurska@wp.pl
FAU - Robaszkiewicz, Jacek
AU  - Robaszkiewicz J
FAU - Wierzbowska, Joanna
AU  - Wierzbowska J
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Poland
TA  - Klin Oczna
JT  - Klinika oczna
JID - 0376614
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - ZL1R02VT79 (Ranibizumab)
SB  - IM
MH  - Antibodies, Monoclonal/*immunology/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Choroidal Neovascularization/*drug therapy/immunology
MH  - Fluorescein Angiography
MH  - Humans
MH  - Injections
MH  - Randomized Controlled Trials as Topic
MH  - Ranibizumab
MH  - Vascular Endothelial Growth Factor A/*immunology
MH  - Visual Acuity/drug effects
MH  - Vitreous Body
MH  - Wet Macular Degeneration/*drug therapy/immunology
EDAT- 2010/09/10 06:00
MHDA- 2010/10/23 06:00
CRDT- 2010/09/10 06:00
PHST- 2010/09/10 06:00 [entrez]
PHST- 2010/09/10 06:00 [pubmed]
PHST- 2010/10/23 06:00 [medline]
PST - ppublish
SO  - Klin Oczna. 2010;112(4-6):147-50.